Literature DB >> 3066295

Reduced biological half-life of plasma prostacyclin in pre-eclampsia.

H Sinzinger1, G Weber.   

Abstract

The biological half-life of prostacyclin was short (5.02 +/- 2.10 min) in 5 out of 7 patients with pre-eclampsia; in the remaining two patients the half-life was normal at 9.78 and 10.27 min, respectively. Four weeks after delivery, the half-life was 5.83 min in one patient but had returned to normal 10.16 +/- 1.77 min) in the other four. In normal pregnancy and healthy non-pregnant females the values were within the normal range. The shortened half-life of PGI2 may account for a decreased local availability of biologically active PGI2 with the consequent decrease in placental perfusion, growth retardation and thrombosis which are often seen in pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3066295     DOI: 10.1007/bf00932266

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  Localisation and stimulation of prostacyclin production in vascular cells.

Authors:  D E MacIntyre; J D Pearson; J L Gordon
Journal:  Nature       Date:  1978-02-09       Impact factor: 49.962

2.  Prostacyclin activity in amniotic fluid in pre-eclampsia.

Authors:  A Bodzenta; J M Thomson; L Poller
Journal:  Lancet       Date:  1980-09-20       Impact factor: 79.321

3.  Maternal vascular prostacyclin activity in pre-eclampsia.

Authors:  F Bussolino; C Benedetto; M Massobrio; G Camussi
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

4.  Diminished prostacyclin formation in umbilical arteries of babies born to women who smoke.

Authors:  C Dadak; C Leithner; H Sinzinger; K Silberbauer
Journal:  Lancet       Date:  1981-01-10       Impact factor: 79.321

5.  Decreased stability of prostacyclin after acute myocardial infarction.

Authors:  H Sinzinger; P Fitscha; B Tiso
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

6.  Plasmatic regulation of vascular prostacyclin in pregnancy.

Authors:  G Remuzzi; C Zoja; D Marchesi; A Schieppati; G Mecca; R Misiani; M B Donati; G de Gaetano
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-14

7.  Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura.

Authors:  Y C Chen; B McLeod; E R Hall; K K Wu
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

8.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

9.  Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension.

Authors:  D J Fitzgerald; S S Entman; K Mulloy; G A FitzGerald
Journal:  Circulation       Date:  1987-05       Impact factor: 29.690

10.  Reduced umbilical artery prostacyclin formation in complicated pregnancies.

Authors:  C Dadak; A Kefalides; H Sinzinger; G Weber
Journal:  Am J Obstet Gynecol       Date:  1982-12-01       Impact factor: 8.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.